Summary for 7P40
| Entry DOI | 10.2210/pdb7p40/pdb |
| EMDB information | 13190 |
| Descriptor | Spike glycoprotein, Variable Light Chain P5C3 (VL), Variable Heavy Chain P5C3 (VH) (3 entities in total) |
| Functional Keywords | spike, antibody, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) More |
| Total number of polymer chains | 9 |
| Total formula weight | 564935.60 |
| Authors | perez, L. (deposition date: 2021-07-09, release date: 2021-10-13, Last modification date: 2024-11-20) |
| Primary citation | Fenwick, C.,Turelli, P.,Perez, L.,Pellaton, C.,Esteves-Leuenberger, L.,Farina, A.,Campos, J.,Lana, E.,Fiscalini, F.,Raclot, C.,Pojer, F.,Lau, K.,Demurtas, D.,Descatoire, M.,Joo, V.S.,Foglierini, M.,Noto, A.,Abdelnabi, R.,Foo, C.S.,Vangeel, L.,Neyts, J.,Du, W.,Bosch, B.J.,Veldman, G.,Leyssen, P.,Thiel, V.,LeGrand, R.,Levy, Y.,Trono, D.,Pantaleo, G. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep, 37:109814-109814, 2021 Cited by PubMed Abstract: Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals. PubMed: 34599871DOI: 10.1016/j.celrep.2021.109814 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.5 Å) |
Structure validation
Download full validation report
